Home
ITOS
ITOS News

Latest iTeos Therapeutics Inc. (ITOS) News on September 8, 2025

MT Newswires

3 months ago

ITeos Therapeutics Insider Sold Shares Worth $1,048,264, According to a Recent SEC Filing

MT Newswires

3 months ago

iTeos Therapeutics Insider Sold Shares Worth $1,592,520, According to a Recent SEC Filing

MT Newswires

3 months ago

iTeos Therapeutics Insider Sold Shares Worth $1,164,405, According to a Recent SEC Filing

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

Zacks

3 months ago

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure

Pharmaceutical Technology

3 months ago

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure

MT Newswires

3 months ago

Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10

MT Newswires

3 months ago

iTeos Therapeutics to Wind Down Operations

iTeos Therapeutics Announces Its Intention to Wind Down Operations

GlobeNewswire

3 months ago

iTeos Therapeutics Announces Its Intention to Wind Down Operations

Cancer drugmaker iTeos to shut down

BioPharma Dive

3 months ago

Cancer drugmaker iTeos to shut down

MT Newswires

4 months ago

Iteos Therapeutics Insider Sold Shares Worth $8,317,364, According to a Recent SEC Filing

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Zacks

4 months ago

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

MT Newswires

4 months ago

Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform

MT Newswires

4 months ago

HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy

GSK and iTeos drop anti-TIGIT drug following trial failure

Clinical Trials Arena

4 months ago

GSK and iTeos drop anti-TIGIT drug following trial failure

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile

Benzinga

4 months ago

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile

MT Newswires

4 months ago

Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating

MT Newswires

4 months ago

GSK, iTeos Therapeutics End Belrestotug Development Program

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

GlobeNewswire

4 months ago

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

iTeos, GSK to shelve TIGIT drug after study setback

BioPharma Dive

4 months ago

iTeos, GSK to shelve TIGIT drug after study setback

Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

Zacks

4 months ago

Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire

4 months ago

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

Simply Wall St.

5 months ago

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

GlobeNewswire

5 months ago

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

Zacks

6 months ago

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

Simply Wall St.

6 months ago

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire

6 months ago

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully

Simply Wall St.

7 months ago

We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

Zacks

8 months ago

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

GlobeNewswire

8 months ago

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

8 months ago

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

TipRanks

9 months ago

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

Clinical Trials Arena

9 months ago

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy

MT Newswires

9 months ago

iTeos Therapeutics Says Deprioritizing Cancer Drug Candidate Inupadenant

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

GlobeNewswire

9 months ago

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

iTeos to Participate in Upcoming Investor Conferences

GlobeNewswire

9 months ago

iTeos to Participate in Upcoming Investor Conferences

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Simply Wall St.

10 months ago

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

10 months ago

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

GlobeNewswire

10 months ago

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc

GuruFocus.com

a year ago

BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc

TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc

GuruFocus.com

a year ago

TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Investor's Business Daily

a year ago

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

MT Newswires

a year ago

Wedbush Raises Price Target on iTeos Therapeutics to $25 From $21, Keeps Outperform Rating

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

Pharmaceutical Technology

a year ago

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

TIGIT drug from iTeos shrinks lung tumors in trial

BioPharma Dive

a year ago

TIGIT drug from iTeos shrinks lung tumors in trial

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

GlobeNewswire

a year ago

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

iTeos to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

iTeos to Participate in Upcoming Investor Conferences

We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate

Simply Wall St.

a year ago

We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

GlobeNewswire

a year ago

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

MT Newswires

a year ago

Wells Fargo Initiates iTeos Therapeutics at Overweight With $31 Price Target

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

MT Newswires

a year ago

ITeos Therapeutics Names David Feltquate Chief Medical Officer

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

GlobeNewswire

a year ago

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial

Pharmaceutical Technology

a year ago

iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial

MT Newswires

a year ago

iTeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

GlobeNewswire

a year ago

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

MT Newswires

a year ago

iTeos, Arcus Shares Drop After Genentech's Lung Cancer Study Misses Endpoints

iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC

Clinical Trials Arena

a year ago

iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?

Simply Wall St.

a year ago

Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating

MT Newswires

a year ago

Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating

MT Newswires

a year ago

iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics Announces $120 Million Registered Direct Offering

GlobeNewswire

a year ago

iTeos Therapeutics Announces $120 Million Registered Direct Offering

iTeos shares jump on TIGIT update; Acelyrin swaps CEOs

BioPharma Dive

a year ago

iTeos shares jump on TIGIT update; Acelyrin swaps CEOs

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire

a year ago

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

GlobeNewswire

2 years ago

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire

2 years ago

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire

2 years ago

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

iTeos to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

iTeos to Participate in Upcoming Investor Conferences

Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?

Domo Ranked #1 Vendor in Dresner Advisory Services’ Analytical Platforms Report

Business Wire

2 years ago

Domo Ranked #1 Vendor in Dresner Advisory Services’ Analytical Platforms Report

Is XPEL, Inc.'s (NASDAQ:XPEL) Stock's Recent Performance A Reflection Of Its Financial Health?

Simply Wall St.

2 years ago

Is XPEL, Inc.'s (NASDAQ:XPEL) Stock's Recent Performance A Reflection Of Its Financial Health?

CrossFirst Bankshares, Inc. (NASDAQ:CFB) Q4 2024 Earnings Call Transcript

Insider Monkey

2 years ago

CrossFirst Bankshares, Inc. (NASDAQ:CFB) Q4 2024 Earnings Call Transcript

Partnership with Evolv Technology a Slam Dunk for Houston’s Toyota Center

Business Wire

2 years ago

Partnership with Evolv Technology a Slam Dunk for Houston’s Toyota Center

P.A.M. Transportation Services (NASDAQ:PTSI) shareholders have earned a 9.6% CAGR over the last five years

Simply Wall St.

2 years ago

P.A.M. Transportation Services (NASDAQ:PTSI) shareholders have earned a 9.6% CAGR over the last five years

Analysts Estimate First Hawaiian (FHB) to Report a Decline in Earnings: What to Look Out for

Zacks

2 years ago

Analysts Estimate First Hawaiian (FHB) to Report a Decline in Earnings: What to Look Out for

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

Business Wire

2 years ago

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

Q3 Earnings Review: Footwear Retailer Stocks Led by Boot Barn (NYSE:BOOT)

StockStory

2 years ago

Q3 Earnings Review: Footwear Retailer Stocks Led by Boot Barn (NYSE:BOOT)

3 Millionaire-Maker Penny Stocks Set to Surge by 1,000%

InvestorPlace

2 years ago

3 Millionaire-Maker Penny Stocks Set to Surge by 1,000%

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

GlobeNewswire

2 years ago

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

Legacy Housing Corporation (NASDAQ:LEGH) insiders have significant skin in the game with 55% ownership

Simply Wall St.

2 years ago

Legacy Housing Corporation (NASDAQ:LEGH) insiders have significant skin in the game with 55% ownership

iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 years ago

iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Procaps Group Reports Third Quarter 2023 Results

Business Wire

2 years ago

Procaps Group Reports Third Quarter 2023 Results

Who Owns More Farmland: Bill Gates Or Gladstone?

Benzinga

2 years ago

Who Owns More Farmland: Bill Gates Or Gladstone?

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

PR Newswire

2 years ago

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Simply Wall St.

2 years ago

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

GDEV announces commencement of self tender offer to purchase for cash a minimum of 15,000,000, up to 20,000,000 of its ordinary shares at a purchase price of $2.00 per ordinary share

GlobeNewswire

2 years ago

GDEV announces commencement of self tender offer to purchase for cash a minimum of 15,000,000, up to 20,000,000 of its ordinary shares at a purchase price of $2.00 per ordinary share

Clover Health to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

GlobeNewswire

2 years ago

Clover Health to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade

Zacks

2 years ago

Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade

Lifezone Metals Announces Significant Mineral Resource Update for its Kabanga Nickel Project in Tanzania

Business Wire

2 years ago

Lifezone Metals Announces Significant Mineral Resource Update for its Kabanga Nickel Project in Tanzania

Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 59% gain

Simply Wall St.

2 years ago

Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 59% gain

PGIM Closed-End Funds declare distributions for December 2023, January and February 2024

Business Wire

2 years ago

PGIM Closed-End Funds declare distributions for December 2023, January and February 2024

Insider Sell Alert: Senior Vice President Daniel Malan Sells Shares of Kelly Services Inc (KELYA)

GuruFocus.com

2 years ago

Insider Sell Alert: Senior Vice President Daniel Malan Sells Shares of Kelly Services Inc (KELYA)

Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?

Zacks

2 years ago

Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire

2 years ago

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher

Zacks

2 years ago

Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher

Is Healthcare Services Group, Inc.'s (NASDAQ:HCSG) Stock Price Struggling As A Result Of Its Mixed Financials?

Simply Wall St.

2 years ago

Is Healthcare Services Group, Inc.'s (NASDAQ:HCSG) Stock Price Struggling As A Result Of Its Mixed Financials?

Despegar.com, Corp. (NYSE:DESP) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Despegar.com, Corp. (NYSE:DESP) Q3 2023 Earnings Call Transcript

Share on Social Networks: